 | • レポートコード：MRC2-11QY03882 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は重症筋無力症治療のグローバル市場について調査・分析したレポートです。種類別（医薬品、手術、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別重症筋無力症治療の競争状況、市場シェア ・世界の重症筋無力症治療市場：種類別市場規模 2015年-2020年（医薬品、手術、その他） ・世界の重症筋無力症治療市場：種類別市場規模予測 2021年-2026年（医薬品、手術、その他） ・世界の重症筋無力症治療市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の重症筋無力症治療市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の重症筋無力症治療市場分析：米国、カナダ ・ヨーロッパの重症筋無力症治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの重症筋無力症治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の重症筋無力症治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの重症筋無力症治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：GlaxoSmithKline、Novartis、Teva Pharmaceutical、Roche、Bristol-Myers Squibb、Apotex、Cipla、Biogen、AbbVie、Bausch Health Companies Inc.、Sun Pharmaceuticals、Fresenius Kabi、Piramal Healthcare、RPG Life Sciences ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.
The Americas accounted for the largest market share of the global myasthenia gravis disease market owing to the growing number of drug manufacturers, increasing awareness about the long-term effects of muscle dystrophy, and rising government funding for the treatment of this disease in the region. Moreover, the U.S. contributes to a significant market share in the global pharmaceutical industry.
Market Analysis and Insights: Global Myasthenia Gravis Disease Treatment Market
The global Myasthenia Gravis Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Myasthenia Gravis Disease Treatment Scope and Market Size
Myasthenia Gravis Disease Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Myasthenia Gravis Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
GlaxoSmithKline
Novartis
Teva Pharmaceutical
Roche
Bristol-Myers Squibb
Apotex
Cipla
Biogen
AbbVie
Bausch Health Companies Inc.
Sun Pharmaceuticals
Fresenius Kabi
Piramal Healthcare
RPG Life Sciences
Market segment by Type, the product can be split into
Medication
Surgery
Others
Market segment by Application, split into
Hospitals
Clinics
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Myasthenia Gravis Disease Treatment Revenue
1.4 Market by Type
1.4.1 Global Myasthenia Gravis Disease Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Medication
1.4.3 Surgery
1.4.4 Others
1.5 Market by Application
1.5.1 Global Myasthenia Gravis Disease Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Myasthenia Gravis Disease Treatment Market Perspective (2015-2026)
2.2 Global Myasthenia Gravis Disease Treatment Growth Trends by Regions
2.2.1 Myasthenia Gravis Disease Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Myasthenia Gravis Disease Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Myasthenia Gravis Disease Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Myasthenia Gravis Disease Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Myasthenia Gravis Disease Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Myasthenia Gravis Disease Treatment Players by Market Size
3.1.1 Global Top Myasthenia Gravis Disease Treatment Players by Revenue (2015-2020)
3.1.2 Global Myasthenia Gravis Disease Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Myasthenia Gravis Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Myasthenia Gravis Disease Treatment Market Concentration Ratio
3.2.1 Global Myasthenia Gravis Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis Disease Treatment Revenue in 2019
3.3 Myasthenia Gravis Disease Treatment Key Players Head office and Area Served
3.4 Key Players Myasthenia Gravis Disease Treatment Product Solution and Service
3.5 Date of Enter into Myasthenia Gravis Disease Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Myasthenia Gravis Disease Treatment Historic Market Size by Type (2015-2020)
4.2 Global Myasthenia Gravis Disease Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020)
5.2 Global Myasthenia Gravis Disease Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Myasthenia Gravis Disease Treatment Market Size (2015-2020)
6.2 Myasthenia Gravis Disease Treatment Key Players in North America (2019-2020)
6.3 North America Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020)
6.4 North America Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Myasthenia Gravis Disease Treatment Market Size (2015-2020)
7.2 Myasthenia Gravis Disease Treatment Key Players in Europe (2019-2020)
7.3 Europe Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020)
7.4 Europe Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020)
8 China
8.1 China Myasthenia Gravis Disease Treatment Market Size (2015-2020)
8.2 Myasthenia Gravis Disease Treatment Key Players in China (2019-2020)
8.3 China Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020)
8.4 China Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Myasthenia Gravis Disease Treatment Market Size (2015-2020)
9.2 Myasthenia Gravis Disease Treatment Key Players in Japan (2019-2020)
9.3 Japan Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020)
9.4 Japan Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Myasthenia Gravis Disease Treatment Market Size (2015-2020)
10.2 Myasthenia Gravis Disease Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020)
11 India
11.1 India Myasthenia Gravis Disease Treatment Market Size (2015-2020)
11.2 Myasthenia Gravis Disease Treatment Key Players in India (2019-2020)
11.3 India Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020)
11.4 India Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Myasthenia Gravis Disease Treatment Market Size (2015-2020)
12.2 Myasthenia Gravis Disease Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020)
12.4 Central & South America Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Details
13.1.2 GlaxoSmithKline Business Overview
13.1.3 GlaxoSmithKline Myasthenia Gravis Disease Treatment Introduction
13.1.4 GlaxoSmithKline Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020))
13.1.5 GlaxoSmithKline Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Myasthenia Gravis Disease Treatment Introduction
13.2.4 Novartis Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Teva Pharmaceutical
13.3.1 Teva Pharmaceutical Company Details
13.3.2 Teva Pharmaceutical Business Overview
13.3.3 Teva Pharmaceutical Myasthenia Gravis Disease Treatment Introduction
13.3.4 Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
13.3.5 Teva Pharmaceutical Recent Development
13.4 Roche
13.4.1 Roche Company Details
13.4.2 Roche Business Overview
13.4.3 Roche Myasthenia Gravis Disease Treatment Introduction
13.4.4 Roche Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
13.4.5 Roche Recent Development
13.5 Bristol-Myers Squibb
13.5.1 Bristol-Myers Squibb Company Details
13.5.2 Bristol-Myers Squibb Business Overview
13.5.3 Bristol-Myers Squibb Myasthenia Gravis Disease Treatment Introduction
13.5.4 Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
13.5.5 Bristol-Myers Squibb Recent Development
13.6 Apotex
13.6.1 Apotex Company Details
13.6.2 Apotex Business Overview
13.6.3 Apotex Myasthenia Gravis Disease Treatment Introduction
13.6.4 Apotex Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
13.6.5 Apotex Recent Development
13.7 Cipla
13.7.1 Cipla Company Details
13.7.2 Cipla Business Overview
13.7.3 Cipla Myasthenia Gravis Disease Treatment Introduction
13.7.4 Cipla Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
13.7.5 Cipla Recent Development
13.8 Biogen
13.8.1 Biogen Company Details
13.8.2 Biogen Business Overview
13.8.3 Biogen Myasthenia Gravis Disease Treatment Introduction
13.8.4 Biogen Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
13.8.5 Biogen Recent Development
13.9 AbbVie
13.9.1 AbbVie Company Details
13.9.2 AbbVie Business Overview
13.9.3 AbbVie Myasthenia Gravis Disease Treatment Introduction
13.9.4 AbbVie Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
13.9.5 AbbVie Recent Development
13.10 Bausch Health Companies Inc.
13.10.1 Bausch Health Companies Inc. Company Details
13.10.2 Bausch Health Companies Inc. Business Overview
13.10.3 Bausch Health Companies Inc. Myasthenia Gravis Disease Treatment Introduction
13.10.4 Bausch Health Companies Inc. Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
13.10.5 Bausch Health Companies Inc. Recent Development
13.11 Sun Pharmaceuticals
10.11.1 Sun Pharmaceuticals Company Details
10.11.2 Sun Pharmaceuticals Business Overview
10.11.3 Sun Pharmaceuticals Myasthenia Gravis Disease Treatment Introduction
10.11.4 Sun Pharmaceuticals Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
10.11.5 Sun Pharmaceuticals Recent Development
13.12 Fresenius Kabi
10.12.1 Fresenius Kabi Company Details
10.12.2 Fresenius Kabi Business Overview
10.12.3 Fresenius Kabi Myasthenia Gravis Disease Treatment Introduction
10.12.4 Fresenius Kabi Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
10.12.5 Fresenius Kabi Recent Development
13.13 Piramal Healthcare
10.13.1 Piramal Healthcare Company Details
10.13.2 Piramal Healthcare Business Overview
10.13.3 Piramal Healthcare Myasthenia Gravis Disease Treatment Introduction
10.13.4 Piramal Healthcare Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
10.13.5 Piramal Healthcare Recent Development
13.14 RPG Life Sciences
10.14.1 RPG Life Sciences Company Details
10.14.2 RPG Life Sciences Business Overview
10.14.3 RPG Life Sciences Myasthenia Gravis Disease Treatment Introduction
10.14.4 RPG Life Sciences Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020)
10.14.5 RPG Life Sciences Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Myasthenia Gravis Disease Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Myasthenia Gravis Disease Treatment Revenue
Table 3. Ranking of Global Top Myasthenia Gravis Disease Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Myasthenia Gravis Disease Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Medication
Table 6. Key Players of Surgery
Table 7. Key Players of Others
Table 8. Global Myasthenia Gravis Disease Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Myasthenia Gravis Disease Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Myasthenia Gravis Disease Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Myasthenia Gravis Disease Treatment Market Share by Regions (2015-2020)
Table 12. Global Myasthenia Gravis Disease Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Myasthenia Gravis Disease Treatment Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Myasthenia Gravis Disease Treatment Market Growth Strategy
Table 18. Main Points Interviewed from Key Myasthenia Gravis Disease Treatment Players
Table 19. Global Myasthenia Gravis Disease Treatment Revenue by Players (2015-2020) (Million US$)
Table 20. Global Myasthenia Gravis Disease Treatment Market Share by Players (2015-2020)
Table 21. Global Top Myasthenia Gravis Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease Treatment as of 2019)
Table 22. Global Myasthenia Gravis Disease Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Myasthenia Gravis Disease Treatment Product Solution and Service
Table 25. Date of Enter into Myasthenia Gravis Disease Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 28. Global Myasthenia Gravis Disease Treatment Market Size Share by Type (2015-2020)
Table 29. Global Myasthenia Gravis Disease Treatment Revenue Market Share by Type (2021-2026)
Table 30. Global Myasthenia Gravis Disease Treatment Market Size Share by Application (2015-2020)
Table 31. Global Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 32. Global Myasthenia Gravis Disease Treatment Market Size Share by Application (2021-2026)
Table 33. North America Key Players Myasthenia Gravis Disease Treatment Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Myasthenia Gravis Disease Treatment Market Share (2019-2020)
Table 35. North America Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 36. North America Myasthenia Gravis Disease Treatment Market Share by Type (2015-2020)
Table 37. North America Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 38. North America Myasthenia Gravis Disease Treatment Market Share by Application (2015-2020)
Table 39. Europe Key Players Myasthenia Gravis Disease Treatment Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Myasthenia Gravis Disease Treatment Market Share (2019-2020)
Table 41. Europe Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Myasthenia Gravis Disease Treatment Market Share by Type (2015-2020)
Table 43. Europe Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Myasthenia Gravis Disease Treatment Market Share by Application (2015-2020)
Table 45. China Key Players Myasthenia Gravis Disease Treatment Revenue (2019-2020) (Million US$)
Table 46. China Key Players Myasthenia Gravis Disease Treatment Market Share (2019-2020)
Table 47. China Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 48. China Myasthenia Gravis Disease Treatment Market Share by Type (2015-2020)
Table 49. China Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 50. China Myasthenia Gravis Disease Treatment Market Share by Application (2015-2020)
Table 51. Japan Key Players Myasthenia Gravis Disease Treatment Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Myasthenia Gravis Disease Treatment Market Share (2019-2020)
Table 53. Japan Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Myasthenia Gravis Disease Treatment Market Share by Type (2015-2020)
Table 55. Japan Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Myasthenia Gravis Disease Treatment Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Myasthenia Gravis Disease Treatment Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Myasthenia Gravis Disease Treatment Market Share (2019-2020)
Table 59. Southeast Asia Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Myasthenia Gravis Disease Treatment Market Share by Type (2015-2020)
Table 61. Southeast Asia Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Myasthenia Gravis Disease Treatment Market Share by Application (2015-2020)
Table 63. India Key Players Myasthenia Gravis Disease Treatment Revenue (2019-2020) (Million US$)
Table 64. India Key Players Myasthenia Gravis Disease Treatment Market Share (2019-2020)
Table 65. India Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 66. India Myasthenia Gravis Disease Treatment Market Share by Type (2015-2020)
Table 67. India Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 68. India Myasthenia Gravis Disease Treatment Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Myasthenia Gravis Disease Treatment Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Myasthenia Gravis Disease Treatment Market Share (2019-2020)
Table 71. Central & South America Myasthenia Gravis Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Myasthenia Gravis Disease Treatment Market Share by Type (2015-2020)
Table 73. Central & South America Myasthenia Gravis Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Myasthenia Gravis Disease Treatment Market Share by Application (2015-2020)
Table 75. GlaxoSmithKline Company Details
Table 76. GlaxoSmithKline Business Overview
Table 77. GlaxoSmithKline Product
Table 78. GlaxoSmithKline Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 79. GlaxoSmithKline Recent Development
Table 80. Novartis Company Details
Table 81. Novartis Business Overview
Table 82. Novartis Product
Table 83. Novartis Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 84. Novartis Recent Development
Table 85. Teva Pharmaceutical Company Details
Table 86. Teva Pharmaceutical Business Overview
Table 87. Teva Pharmaceutical Product
Table 88. Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 89. Teva Pharmaceutical Recent Development
Table 90. Roche Company Details
Table 91. Roche Business Overview
Table 92. Roche Product
Table 93. Roche Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 94. Roche Recent Development
Table 95. Bristol-Myers Squibb Company Details
Table 96. Bristol-Myers Squibb Business Overview
Table 97. Bristol-Myers Squibb Product
Table 98. Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 99. Bristol-Myers Squibb Recent Development
Table 100. Apotex Company Details
Table 101. Apotex Business Overview
Table 102. Apotex Product
Table 103. Apotex Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 104. Apotex Recent Development
Table 105. Cipla Company Details
Table 106. Cipla Business Overview
Table 107. Cipla Product
Table 108. Cipla Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 109. Cipla Recent Development
Table 110. Biogen Business Overview
Table 111. Biogen Product
Table 112. Biogen Company Details
Table 113. Biogen Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 114. Biogen Recent Development
Table 115. AbbVie Company Details
Table 116. AbbVie Business Overview
Table 117. AbbVie Product
Table 118. AbbVie Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 119. AbbVie Recent Development
Table 120. Bausch Health Companies Inc. Company Details
Table 121. Bausch Health Companies Inc. Business Overview
Table 122. Bausch Health Companies Inc. Product
Table 123. Bausch Health Companies Inc. Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 124. Bausch Health Companies Inc. Recent Development
Table 125. Sun Pharmaceuticals Company Details
Table 126. Sun Pharmaceuticals Business Overview
Table 127. Sun Pharmaceuticals Product
Table 128. Sun Pharmaceuticals Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 129. Sun Pharmaceuticals Recent Development
Table 130. Fresenius Kabi Company Details
Table 131. Fresenius Kabi Business Overview
Table 132. Fresenius Kabi Product
Table 133. Fresenius Kabi Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 134. Fresenius Kabi Recent Development
Table 135. Piramal Healthcare Company Details
Table 136. Piramal Healthcare Business Overview
Table 137. Piramal Healthcare Product
Table 138. Piramal Healthcare Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 139. Piramal Healthcare Recent Development
Table 140. RPG Life Sciences Company Details
Table 141. RPG Life Sciences Business Overview
Table 142. RPG Life Sciences Product
Table 143. RPG Life Sciences Revenue in Myasthenia Gravis Disease Treatment Business (2015-2020) (Million US$)
Table 144. RPG Life Sciences Recent Development
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myasthenia Gravis Disease Treatment Market Share by Type: 2020 VS 2026
Figure 2. Medication Features
Figure 3. Surgery Features
Figure 4. Others Features
Figure 5. Global Myasthenia Gravis Disease Treatment Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Myasthenia Gravis Disease Treatment Report Years Considered
Figure 10. Global Myasthenia Gravis Disease Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Myasthenia Gravis Disease Treatment Market Share by Regions: 2020 VS 2026
Figure 12. Global Myasthenia Gravis Disease Treatment Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Myasthenia Gravis Disease Treatment Market Share by Players in 2019
Figure 15. Global Top Myasthenia Gravis Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease Treatment as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Myasthenia Gravis Disease Treatment Revenue in 2019
Figure 17. North America Myasthenia Gravis Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Myasthenia Gravis Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Myasthenia Gravis Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Myasthenia Gravis Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Myasthenia Gravis Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Myasthenia Gravis Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Myasthenia Gravis Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
重症筋無力症の世界市場（～2026年） Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be …- 重症筋無力症治療薬の世界市場（～2026年） Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and …
- メニエール病治療の世界市場（～2026年） Meniere’s disease is a disorder of middle ear that causes vertigo, ringing sound in the ear and hearing problems. In most of the cases this disease only affects one ear. Meniere’s disease can affect anyone but the prevalence is on a higher side in people aged from 20-50. This is a chronic disease bu…
- クラッベ病治療の世界市場（～2026年） Krabbe disease (KD) (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessi…
- ニューカッスル病治療の世界市場（～2026年） Newcastle Disease is a highly contagious disease of avian species especially poultry caused by avian Paramyxovirus type 1 (APMV-1). The North America is dominating and contributed the leading shares to the global Newcastle Disease Treatment market in terms of revenue and expected to register a signi…